SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors

Launched by BRITISH COLUMBIA CANCER AGENCY · Apr 15, 2025

Keywords

ClinConnect Summary

The SABR PRIMER trial is looking at a special type of treatment called stereotactic ablative radiotherapy (SABR) to see if it can help control tumor growth in patients with metastatic breast cancer, which means cancer that has spread from the breast to other parts of the body. The trial will also check how long patients live after treatment, how long they can stay without their cancer getting worse, and when they might need to switch to other treatments. Additionally, researchers will monitor any side effects from the treatment, such as skin irritation, swelling, and nerve issues.

To be eligible for this trial, patients should be at least 18 years old and have a specific type of advanced breast cancer that can be measured and treated with radiation. They should also be receiving or planning to receive other cancer treatments. The study is not yet recruiting participants, but once it starts, those who join will have the opportunity to help researchers learn more about how this treatment works and its effects. It's important for participants to be ready to answer some questions about their experiences during the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Pathologically confirmed AJCC 7th/8th edition Stage IV invasive ductal carcinoma or invasive lobular carcinoma of the breast.
• • 2. Measurable disease in the breast, suitable to receive radiotherapy.
• • 3. Receiving or planned to receive systemic therapy.
• • a. The following should be held for the duration of treatment: cytotoxic chemotherapy, CDK4/6 inhibitors, T-DXd
• • 4. Patients are allowed to have SABR for oligometastatic disease as clinically indicated
• • 5. Age 18 or older
• • 6. ECOG Performance Status 0-2
• • 7. Life expectancy greater than 6 months
• • 8. Able and willing to provide informed consent
• • 9. Able to complete patient reported outcome questionnaires
• Exclusion Criteria:
• • 1. Contraindications to radiotherapy, including a history of SLE, systemic scleroderma, IPF, ataxia telangiectasia, pregnancy
• • 2. Previous history of locoregional radiotherapy to the ipsilateral breast